Stay up-to-date with the latest Sciety news
Discover the latest updates on our company and investments in life science

EMPE Diagnostics, which has developed a rapid test for the diagnosis and resistance determination of tuberculosis, the world’s deadliest infectious disease, has recently completed a share issue of SEK 23.5 million with Sciety. The company has also received a grant of SEK 25 million from EU Horizon 2020. The new…
Read morePRESS RELEASE. Capitainer, a Swedish Medtech company that supplies intelligent solutions for self-sampling of blood and plasma, recently completed a share issue of SEK 31 million with Sciety and its investment syndicate. The investors demonstrated strong interest, and the share issue was fully subscribed in two days. The new capital…
Read moreNEW COMPANY AT SCIETY. Most blood sampling is still performed by qualified healthcare personnel at care facilities, but new technology that enables simple and reliable home sampling is now changing the landscape. Sciety finances a Swedish company that is at the forefront of the technology shift. Blood sampling has an…
Read morePRESS RELEASE. The American biotechnology company 10x Genomics acquires the Swedish company Cartana, which was financed by the Sciety investment syndicate two years ago. Three years after launch, the Swedish biotechnology company Cartana will be part of the Nasdaq-listed American company 10x Genomics––the market leader in single-cell analysis technology. The…
Read moreSciety had the opportunity to ask a few questions to Mats Nilsson, professor at SciLifeLab and co-founder of EMPE Diagnostics and several other biotechnology companies. In the interview he talks about EMPE Diagnostics’ planned establishment in India and and about the need for diagnostic tools in order to use the drugs that are available. He gives an insight into SciLifeLab as the platform for developing ideas and also his view on the role of research in society.
Read moreThe Sciety syndicate invests in Synartro, which uses existing drugs with proven efficacy to develop an improved drug treatment of knee osteoarthritis. The new capital will be used to complete the pre-clinical development. The company plans to go public to raise capital for phase 1 clinical trials in 2021. Synartro’s…
Read moreSciety talks with Pavan Asalapuram, co-founder of EMPE Diagnostics, a company that develops rapid diagnostic solutions for infectious diseases, with a special focus on tuberculosis––a major public health problem in big parts of the world. EMPE’s test can within two hours identify whether a person has TB and whether it…
Read moreThe Sciety investment syndicate recently made an investment of 9.1 million SEK in the company Cavis Technologies, which has developed Wirecath®––a patent-pending product for the diagnosis of coronary heart diseases. The new capital will be used to establish sales on the European market. “Only in Europe, over 1.5 million people…
Read moreNew diagnostic technology can reduce mortality in one of the world’s most common infectious diseases
Today, Sciety wants to pay attention to World TB Day, which aims to highlight the extensive health, social and economic consequences of tuberculosis. Tuberculosis is a contagious infectious disease that primarily affects the lungs but also other organs. It is an airborne disease that spreads when a person with tuberculosis…
Read moreOne of the most common causes of death in the world comes from diseases of the coronary arteries, the heart’s own blood vessels. Coronary artery disease occurs through constriction of the coronary arteries that leads to a pressure drop which can cause heart attack and stroke. Diseases of the coronary…
Read more